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Abstract
Abnormal activity of red cell KCl cotransport (KCC) is involved in pathogenesis of sickle cell anaemia (SCA). KCC-mediated
solute loss causes shrinkage, concentrates HbS, and promotes HbS polymerisation. Red cell KCC also responds to various stimuli
including pH, volume, urea, and oxygen tension, and regulation involves protein phosphorylation. The main aim of this study
was to investigate the role of the WNK/SPAK/OSR1 pathway in sickle cells. The panWNK inhibitor WNK463 stimulated KCC
with an EC50 of 10.9 ± 1.1 nM and 7.9 ± 1.2 nM in sickle and normal red cells, respectively. SPAK/OSR1 inhibitors had little
effect. The action of WNK463 was not additive with other kinase inhibitors (staurosporine and N-ethylmaleimide). Its effects
were largely abrogated by pre-treatment with the phosphatase inhibitor calyculin A. WNK463 also reduced the effects of
physiological KCC stimuli (pH, volume, urea) and abolished any response of KCC to changes in oxygen tension. Finally,
although protein kinases have been implicated in regulation of phosphatidylserine exposure, WNK463 had no effect. Findings
indicate a predominant role for WNKs in control of KCC in sickle cells but an apparent absence of downstream involvement of
SPAK/OSR1. Amore complete understanding of the mechanisms will inform pathogenesis whilst manipulation ofWNK activity
represents a potential therapeutic approach.






ORS1 The oxidative stress response kinase 1 (OSR1)
RVD Regulatory volume decrease
RVI Regulatory volume increase
SCA Sickle cell anaemia
SLC Solute-linked carrier transport protein
SPAK The SPS1-related proline/alanine-rich kinase
(SPAK or STK39)
WNK “With no lysine (K)” kinases
Introduction
The family of cation-chloride cotransporters (CCCs) comprise
the Na+-Cl-, the Na+-K+-Cl-, and the K+-Cl- cotransporters
(NCC, NKCCs, and KCCs). They have been identified in
many tissues – notably red cells, epithelia, and neurons – in
What is already known:
• KCC is important in SCA mediating red cell solute loss and thereby
encourages sickling
• Control involves protein phosphorylation – in other tissues the WNK
pathway is involved
What this study adds:
• First evidence for a predominant role ofWNKs controllingKCC activity
in sickle cells
Clinical significance:
• KCC activity causes red cell shrinkage, promoting HbS polymerisation
and its deleterious sequelae
•WNK activators, targeted to red cells, would be useful therapeutically in
SCA
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which they contribute extensively to ion and water homeosta-
sis, both cellular and transepithelial [23]. Many of these trans-
porters were functionally identified in the late 1970s/early
1980s as Cl--dependent cation fluxes, with red cells and
Ehrlich ascites tumour cells constituting pivotal model tissues
[18, 28, 32, 38]. Their molecular identities were subsequently
established a decade or so later [24, 46, 57]. There are two
NKCC isoforms – NKCC1 is ubiquitous whilst NKCC2 is
confined to the kidney – which are encoded by two genes,
SLC12A2 and SLC12A1, respectively. In addition, there are
four KCC isoforms, encoded by SLC12A4-7 – of which
SLC12A5 (KCC2) is found only in neurons [23]. The sole
NCC isoform, SLC12A3, is also found in the kidney [24].
Usually, NCC and NKCCs mediate net movement of
ions into cells, whilst KCCs move ions outwards. In red
cells, CCCs are associated physiologically with volume
regulatory processes, with NKCC involved in ion accu-
mulation and swelling in response to shrinkage (regulato-
ry volume increase or RVI) and KCC in ion loss and
shrinkage following swelling (regulatory volume de-
crease, RVD) (reviewed by [9]). Physiological RVI and
RVD responses, however, are not present in mature red
cells from humans, although they may participate in vol-
ume regulation during erythropoiesis [21, 30]. Besides
volume, red cell CCCs also respond to a number of other
stimulus modalities including pH, urea, and oxygen ten-
sion [4, 25, 37, 43]. These other stimuli may represent
more important modulators of KCC activity than that of
volume. In addition, various stimuli, like swelling and
shrinkage or oxygenation and deoxygenation, often have
opposite effects on the activities of red cell NKCC and
KCC [44], and these systems are often reciprocally
coordinated.
In human red cells, the major significance of KCC is prob-
ably pathological in patients with sickle cell anaemia (SCA,
HbSS genotype). In sickle cells, a single mutation results in
the replacement of normal adult HbAwith HbS. The substitu-
tion of glutamic acid with valine at position 6 of the Hb β
chain allows HbS to polymerise upon deoxygenation – the
initial event in the pathogenesis of SCA [5]. In patients’ red
cells, over activity and also abnormal regulation of KCC con-
tribute to excessive solute loss, with osmotically obliged water
following [4, 6, 26, 35]. The ensuing shrinkage is important
because increased concentration of HbS ([HbS]) markedly
encourages the probability of HbS polymerisation and sick-
ling, since the lag time to polymerisation of HbS upon deox-
ygenation is inversely proportional to a very high power of its
concentration ([HbS]-15-30 is often quoted [19]). Numerous
damaging sequelae follow, including altered rheology, in-
creased fragility, intravascular haemolysis, scavenging of ni-
tric oxide, increased red cell stickiness, thrombus formation
and microvascular occlusion, and result in the plethora of
clinical signs seen in SCA patients [48, 53]. Solute loss is
probably a very early event in the pathogenesis of the disease
following HbS polymerisation. Considerable effort has there-
fore been expended on understanding the underlying mecha-
nisms and in the design of potential pharmacological inhibi-
tors [29].
It was apparent some 30 years ago that protein phosphory-
lation was a key component in regulation of KCC activity, in
both normal and sickle red cells from humans and across
vertebrate species [10, 22, 33, 34]. Net dephosphorylation of
the transporter, or a regulatory protein, was associated with
higher KCC activity and net phosphorylation with reduced
activity [10]. Notwithstanding, most work has been carried
out using more or less specific pharmacological inhibitors
(staurosporine, genistein, N-ethylmaleimide, calyculin A),
and the identity of the specific enzymes involved remains
unclear [10, 54].
An important breakthrough came when it was found
that some cases of hypertension were caused by mutations
in the WNK kinases [56]. It was then shown that some
CCCs were regulated by two Ste20 group kinases, the
oxidative stress response kinase 1 (OSR1) and the SPS1-
related proline/alanine-rich kinase (SPAK or STK39) [16,
17, 47]. Later, from work mainly on epithelia, notably the
kidney, it was found that the “with no lysine (K)” kinases
(WNKs) both stimulated NKCC and inhibited KCC in a
coordinate way, often working via downstream activation
of SPAK/OSR1 [1, 14, 36]. In red cells, the situation
remained unclear until more recently two papers have also
revealed a role for WNKs in control of both KCC and
NKCC. Working principally with the HEK293 cell line,
but also with human red cells [50], showed that WNK1
inhibition played a role in stimulation of red cell KCC by
swelling. Latterly, Low’s group has used transgenic mice
to identify an excitatory role for WNK1 for OSR1 and, in
regulation of the coordinate transporter, NKCC, upon de-
oxygenation [63].
Nevertheless, although in other tissues WNKs have been
shown to modulate KCC activity, their role in mediating
many of the stimuli affecting red cell KCC activity and their
function in sickle cells remain poorly studied. In this paper,
we used a the pan WNK inhibitor, WNK463, to assess the
role of WNKs in regulation of KCC in red cells, mainly
from SCA patients but also from normal individuals
(HbAA genotype), assessing its interaction with less specif-
ic pharmacological modulators of protein phosphorylation
(staurosporine, NEM and calyculin A) and with the more
physiologically important stimuli (pH, volume, urea, and
oxygen). Results represent the first demonstration for a
pre-eminent role for WNKs in modulation of KCC activity
in sickle cells, suggesting a potential key target for chemo-
therapeutic modulation. By contrast, pharmacological re-
sults suggest that participation of the downstream kinases
SPAK/OSR1 in regulation of KCC activity was lacking.
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Materials and methods
Materials
All chemicals and inhibitors came from Sigma-Aldrich
(Poole, Dorset, UK) unless otherwise stated. WNK463 came
from AdooQ Bioscience (Irvine, CA, USA), STOCK2S-
26016 from Tocris Bioscience (Bristol, UK), and HK01 from
ChemBridge Corporation (SanDiego, CA, USA). 86Rb+ came
from PerkinElmer (Beaconsfield, Bucks., UK). Nitrogen was
from BOC Ltd (Guildford, Surrey, UK).
Blood samples
Consented samples were acquired with ethical approval from
patients with sickle cell anaemia (SCA, genotype HbSS –
termed HbSS cells) or normal individuals (genotype HbAA
– termed HbAA cells) using EDTA as anticoagulant (REC
reference number 16/LO/1309). Occasionally routine
discarded blood samples left over from clinical assays were
also used. All samples were obtained from the Sickle Cell
Clinic at King’s College Hospital and were anonymised.
Samples were refrigerated until used, within 2 days. Whole
blood was then washed in Cl--free saline (N-MBS, see below)
to remove plasma, buffy coat, and also Cl-, and red cells are
stored on ice until required.
Salines and inhibitors
Nitrate-containing MOPS-buffered saline (N-MBS) com-
prised (in mM) NaNO3 145, MOPS 10, glucose 5, and pH
7.4 at 37 °C. Cl--containing MBS (Cl-MBS) had similar com-
position but with NaCl replacing NaNO3. Wash solution (W-
MBS) was isotonic MgCl2 solution: MgCl2 107, MOPS 10,
and pH 7.4 at 0 °C.
Tonometry
KCC activity in human red cells is O2-sensitive [26]. It was
therefore important to regulate O2 tension during incubation.
Cells were gently rotated at 37 °C in Eschweiler tonometers,
coupled to a Wösthoff gas mixing pump to set the O2 tension
at the requisite level from 150 mmHg oxygen to 0 by mixing
pre-warmed and humidified air and N2. Typically, cells were
placed in the tonometers at tenfold the haematocrit (Hct) need-
ed for transport assay and equilibrated at the requisite O2 ten-
sion. They were then diluted tenfold into test tubes, also pre-
equilibrated at the required O2 level. Tubes were also gassed
during incubation, but not bubbled (to prevent red cell lysis).
Humidified gas is necessary to prevent dehydration of the
samples and to prevent condensation; all glassware and tubing
were submerged and kept at 37 °C.
Measurement of KCC activity
86Rb+ was used as a K+ congener. After dilution of the red cell
samples into the test tubes, the influx was started by addition
of 86Rb+ (final activity about 0.05 MBq.ml-1) to warm (37 °C)
cell suspensions. 86Rb+ was added in a solution of 150 mM
KNO3 added at a 1 in 20 dilution to give a final extracellular
[K+] of 7.5 mM. The duration of uptake here was 10 min,
control experiments have established that uptake is linear over
this time period, and determinations were usually carried out
in triplicates. Uptake was stopped by diluting aliquots of the
cell suspension into ice-cold W-MBS. Unincorporated 86Rb+
was removed by centrifugation (10 s at 15,000 g), aspiration
of supernatant, and addition of further wash solution (4
washes and 5 spins in total). After each centrifugation step,
cells were resuspended by gentle vortexing. Following the
final wash, the cell pellet was lysed with Triton X-100
(0.1%) and protein (mainly haemoglobin in the case of red
blood cells) precipitated with trichloroacetic acid (TCA,
5%). A final centrifugation step was used to separate off the
clear, colourless supernatant before counting. Activity was
measured as Čerenkov radiation by liquid scintillation
(Packard Tri-carb 2800TR). The test tubes contained transport
inhibitors in Cl-MBS or N-MBS as required. KCC activity
was calculated as the Cl--dependent K+ uptake and given as
mmol K+(l cells.h)-1. Ouabain (100 μM) and bumetanide (10
μM) were present during all influx assays to inhibit K+ uptake
via the Na+/K+ pump and Na+-K+-2Cl- cotransporter
(NKCC), respectively.
Inhibitor studies
For most experiments, red cells were pre-incubated with in-
hibitors for 30 min at 20% haematocrit (Hct) at pH 7.4 under
isotonic conditions (290mOsm.kg-1) at 37 °C. They were then
equilibrated in tonometers either fully oxygenated or at the
required oxygen tension (Fig. 6) for a further 20 min. Red
cells were then diluted tenfold into test tubes at the required
pH (pH 7 or 7.4), tonicity (10% shrunken through addition of
hypertonic sucrose or 10% swollen through addition of water)
or with added urea (500 mM), and KCC activity measured.
For the experiments in Fig. 1b, pre-incubation with WNK463
was varied from 0 up to 30 min before equilibrating in tonom-
eters in the presence WNK463 for 20 min and subsequent
measuring of KCC activity. For combinations of WNK463
and staurosporine, NEM, or calyculin A, red cells were ex-
posed sequentially to each inhibitor (or DMSO solvent) for 30
min.
Phosphatidylserine exposure
Phosphatidylserine exposure was measured by FACS using
FITC-labelled lactadherin (see [12] for details).
Pflugers Arch - Eur J Physiol (2019) 471:1539–1549 1541
Statistics
Data are given as means ± S.E.M. for samples from n different
individuals. Comparisons with and without inhibitors were
carried out in paired samples, and statistical analysis was
made using student’s t test. A value of p < 0.05 was taken as
significant.
Results
The effect of WNK463 on KCl cotransport in human
red cells
In the first series of experiment, the effect of the pan WNK
inhibitor WNK463 was examined in red cells from both nor-
mal individuals (termed HbAA cells) and patients with SCA
(termed HbSS cells). Initially, its concentration dependence
was investigated. WNK463 increased KCC activity in both
HbAA and HbSS cells, with an EC50 of 7.9 ± 1.2 nM and
10.9 ± 1.6 nM, respectively (Fig. 1a). The time course of the
effect of WNK463 was also determined. After equilibrating in
the presence of WNK463 in fully oxygenated conditions for
20 min, the inhibitor significantly increased KCC activity by
about fivefold (Fig. 1b). With additional periods of pre-
incubation prior to oxygen tension equilibration, the stimula-
tory effect of WNK463 increased, becoming maximal after
20 min pre-incubation. On the basis of these preliminary ex-
periments, a concentration of 40 nM WNK463 and a pre-
incubation time of 30 min were chosen for subsequent work.
In the absence of Cl-, in N-MBS, K+ influxes were 0.65 ± 0.10
and 0.70 ± 0.20 mmol.(l cells.h)-1 in normal and sickle red
cells in the absence of WNK463 and 0.74 ± 0.10 and 0.78 ±
0.15 in its presence (40 nM), means ± S.E.M., n = 3 (all N.S.),
confirming that the major effect of WNK463 was mediated
via KCC activity. The following is largely restricted to work in
red cells from SCA patients, but similar findings were obtain-
ed with those from normal HbAA individuals and are given in
brief.
The effect of combinations of WNK463
and staurosporine, N-ethylmaleimide (NEM),
and calyculin A in HbSS cells and HbAA cells
Staurosporine (100 μM) represents one of the main protein
kinase (PK) inhibitors used to stimulate KCC activity in red
cells [10]. Its effects were compared with those of WNK463
(Fig. 2). When incubated with each PK inhibitor alone, the
stimulatory effects of WNK463 and staurosporine were simi-
lar, albeit slightly greater forWNK463. Sequential application
of the two inhibitors also gave similar levels of activity al-
though addition of WNK463 before staurosporine appeared
to slightly increase KCC activity further compared to either
inhibitor alone. However, the actual increase of KCC activity
was only 10.6 ± 5.1% compared to WNK463 alone, suggest-
ing a similar target kinase for both reagents.
A second putative PK inhibitor used to stimulate KCC
activity in red cells has been the thiol-reacting reagent N-
ethylmaleimide (NEM; 100 μM) [20, 38]. When compared
with WNK463, NEM alone or in combination with
WNK463, NEM gave significantly lower levels of KCC ac-
tivity compared toWNK463 alone, whether applied prior to or
after WNK463 (Fig. 3). Again, there was no indication of
additive effects of the two reagents. As NEM/WNK463
Fig. 1 Effect of WNK463 on KCl cotransport (KCC) activity in red cells
from normal individuals (HbAA) and patients with sickle cell anaemia
(SCA). Red cells from patients homozygous for SCA (20% haematocrit,
Hct) or healthy individuals (40% Hct) were pre-incubated in N-MBS for
30min at 37 °C in air in the presence of 0–40 nMWNK463, unless stated
otherwise. They were then equilibrated in Eschweiler tonometers for
20 min in air (150 mmHg O2) in the continued presence of WNK463,
after which aliquots were diluted tenfold into flux tubes. KCC activity
was measured as Cl--dependent K+-influx for 10 min at an extracellular
[K+] of 7.5mM. KCC activity is given inmmol.(l cells.h)-1. Ouabain (100
μM) and bumetanide (10μM)were present in all experiments. a Effect of
0–40 nMWNK463 onKCC activity. KCC activity was normalised to that
at 40 nM WNK463 and EC50 calculated using nonlinear regression. b
Effect of duration of pre-incubation with 40 nM WNK463 on KCC
activity in HbSS cells. Symbols represent means ± SEM, n = 3. * p <
0.05, ** p < 0.01 compared to red cells incubated in the absence of
WNK463
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combinations always reduced KCC activity below that of
WNK463 alone, it suggested that effects other than PK inhi-
bition were present.
The protein phosphatase inhibitor calyculin A (100 nM)
has been shown to inhibit KCC activity in red cells and to
prevent subsequent stimulation by PK inhibitors following
pre-incubation with calyculin A [52]. These observations sug-
gest that dephosphorylation of the regulatory site controlling
KCC activity involves a calyculin A-sensitive phosphatase
PP1 and PP2a [2, 3]. As observed previously, calyculin A on
its own inhibited KCC activity below that in control cells (Fig.
4). Following WNK463 addition, however, calyculin A had
minimal effect. When added prior to WNK463, calyculin A
greatly reduced the stimulatory effect of subsequent addition
of WNK43. These findings are consistent with the WNK
phosphoresidue target also being dephosphorylated by a
calyculin A-sensitive phosphatase.
Similar findings were obtained with red cells from normal
individuals (HbAA). Control K+ influxes in the absence of
protein kinase/phosphatase inhibitors were 0.2 to 0.3 mmol.(l
cells.h)-1. In the presence of staurosporine (100 μM) and
NEM (1 mM), these increased to 3.41 ± 0.86 and 3.01 ±
0.60 mmol.(l cells.h)-1, respectively. When treated with com-
bination of staurosporine or NEM and WNK463 (40 nM),
influxes were 3.5 ± 0.5 and 3.55 ± 0.80 mmol.(l cells.h)-1
(means ± S.E.M, n = 3; N.S. cf staurosporine and NEM alone),
respectively – showing that the action of WNK463 and
staurosporine/NEM was not additive. With calyculin A (100
nM), influxes were reduced from 0.30 ± 0.07 to 0.20 ± 0.06
mmol.(l cells.h)-1 increasing to 3.40 ± 0.82 with WNK463
Fig. 3 Effect of N-ethylmaleimide (NEM) and WNK463 on KCC
activity in red cells from patients with SCA. Red cells (20% Hct) were
pre-incubated in N-MBS sequentially for two periods of 30 min in the
presence of vehicle (DMSO) or drug (WNK463 40 nM or NEM 1 mM),
as indicated. They were then equilibrated in Eschweiler tonometers for
20min at 150 mmHg in the continued presence ofWNK463 and/or NEM
and KCC activity measured as described in the legend to Fig. 1.
Histograms represent means ± SEM, n = 4. * p < 0.05, ** p < 0.01
compared to red cells incubated in the absence of WNK463; # p < 0.05
between groups as indicated
Fig. 2 Effect of staurosporine andWNK463 on KCC activity in red cells
from patients with SCA. Red cells (20% Hct) were pre-incubated in N-
MBS sequentially for two periods of 30 min in the presence of vehicle
(DMSO) or drug (WNK463 40 nM or staurosporine 100 μM), as
indicated. They were then equilibrated in Eschweiler tonometers for
20 min at 150 mmHg in the continued presence of WNK463 and/or
staurosporine and KCC activity measured as described in the legend to
Fig. 1. Histograms represent means ± SEM, n = 4. * p < 0.05, ** p < 0.01
compared to red cells incubated in the absence of WNK463; # p < 0.05
between groups as indicated
Fig. 4 Effect of calyculin A and WNK463 on KCC activity in red cells
from patients with SCA. Red cells (20% Hct) were pre-incubated in N-
MBS sequentially for two periods of 30 min in the presence of vehicle
(DMSO) or drug (WNK463 40 nM or calyculin A 100 nM), as indicated.
They were then equilibrated in Eschweiler tonometers for 20 min at
150 mmHg in the continued presence of WNK463 and/or calyculin A
and KCC activity measured as described in the legend to Fig. 1.
Histograms represent means ± SEM, n = 6. ** p < 0.01 compared to
red cells incubated in the absence of WNK463; # p < 0.05, ## p < 0.01
between groups as indicated.
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alone, and in combination with WNK463 after calyculin A,
they were 0.43 ± 0.16 mmol.(l cells.h)-1, showing that pre-
treatment of red cells with the protein phosphatase inhibitor
calyculin A prevented KCC in normal red cells from
responding to WNK463.
The effect of combinations of WNK463
and physiological stimuli modulating KCC activity
in HbSS cells
The effect of changes in pH and volume change and also
incubation with high concentrations of urea was compared
in control HbSS cells and following pre-incubation with
WNK463. All three stimuli significantly elevated KCC activ-
ity – as shown previously [25] – but none stimulated activity
to the extent achieved by WNK463 alone (Fig. 5a–c).
Notwithstanding all three were still able to increase KCC ac-
tivity following pre-incubation with WNK463, although the
fold changes in activity were considerably reduced compared
with those in cells not pre-incubated with WNK463 (Fig. 5d).
These findings may indicate that whilst these other stimuli
may act mainly through WNK inhibition, their effect must
also be mediated via some other mechanism, as suggested
for the coordinate transport NKCC in HEK293 cells [31].
Conversely, it may be that pre-incubation was insufficient to
completely abrogateWNK activity. A similar pattern was also
found in normal HbAA red cells.
In the case of red cell NKCC,WNK1 appears to be respon-
sible for increased activity following deoxygenation [63].
KCC activity is also oxygen dependent, although in a recip-
rocal fashion being activated by oxygenation rather than de-
oxygenation. In red cells from normal individuals, KCC is
maximally active under conditions of full oxygenation, with
activity declining as oxygen tension is lowered such that the
transporter is inactive when cells are fully deoxygenated [26].
In sickle cells, KCC activity has an abnormal oxygen depen-
dence, with highest activity in fully oxygenated and fully de-
oxygenated cells with a nadir at about the PO2 required for
half maximal saturation of Hb with oxygen [26]. This abnor-
mal oxygen dependence was confirmed here (Fig. 6). The
interaction ofWNK and oxygen tension was also investigated.
When pre-incubated with WNK463, KCC activity was
Fig. 5 Effect of WNK463 on physiological stimuli of KCC in red cells
from patients with SCA. Red cells (20% Hct) were pre-incubated in N-
MBS in the presence or absence of WNK463 (40 nM) at 37 °C in air.
They were then equilibrated in Eschweiler tonometers for 20 min at 150
mmHg, after which aliquots were diluted tenfold into flux tubes
containing buffers varying in pH, osmolarity, or urea content, all in the
continued presence or absence of WNK463, and KCC activity was
measured as described in the legend to Fig. 1. a Effect of WNK463 on
pH-dependent KCC activity, n = 6. b Effect ofWNK463 on KCC activity
in 10% shrunken (SH) or 10% swollen (SW) red cells, n = 5. c Effect of
WNK463 on urea-induced KCC activity, n = 6. d Impact of WNK463 on
pH, volume, and urea-stimulated KCC activity. Histograms represent
means ± SEM of n individual samples. * p < 0.05, ** p < 0.01, *** p <
0.001 compared to indicated condition, # p < 0.05 compared to fold
change in absence of WNK463
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maximally stimulated and became insensitive to changes in
oxygen tension. These findings suggest a role for WNK in
mediating the oxygen sensitivity of KCC, as well as for that
of NKCC.
The effect of inhibitors of SPAK/OSR1
In many cases, SPAK/OSR1 are implicated as a downstream
target of WNKs. Following phosphorylation by WNKs,
SPAK/OSR1 then carry out phosphorylation of the relevant
CCC. The effects of several SPAK/OSR1 inhibitors
(STOCK2S-26016, closantel, and rafoxanide) as well as of
HK01, an inhibitor of MO25, a scaffolding protein that in-
creases SPAK/OSR1 activity > 100-fold, were investigated.
None of these inhibitors, however, gave comparable effects to
that ofWNK463. STOCK2S-26016 and HK01 did stimulate a
Cl--dependent K+ influx, but effects were minimal (Fig. 7a
and b for healthy HbAA red cells) whilst 40 nM WNK463
increased it about tenfold, from 0.35 ± 0.04 to 3.1 ± 0.2
mmol.(l cells.h)-1 (n = 24). In comparison, in red cells from
HbSS patients Cl--dependent K+-influx increased from 0.48 ±
0.2 to 1.31 ± 0.3 mmol.(l cells.h)-1 in the presence of HK01 (p
< 0.021; n = 3) and from 0.70 ± 0.10 to 3.3 ± 0.2 mmol.(l
cells.h)-1 (n = 3) in the presence of 40 nM WNK463. Both
closantel and rafoxanide also increased K+ influx, but in this
case, transport was not Cl--dependent suggesting a nonspecif-
ic increase in membrane permeability rather than stimulation
of KCC (data not shown). These findings are evidence against
a major role for SPAK/OSR1 in the phosphorylation pathway
modulating red cell KCC activity.
The effect of WNK463 on phosphatidylserine
exposure
As well as solute loss through KCC activity and other path-
ways, phosphatidylserine (PS) exposure is also implicated in
the pathogenesis of SCA as it is prothrombotic and contributes
to both anaemia and ischaemia. It has also been shown to be
affected by protein phosphorylation and is inhibited by some
protein kinase inhibitors, notably PKC inhibitors [55]. It was
therefore pertinent to determine whether WNK inhibition had
any effect on PS externalisation. There was no apparent effect
of WNK463, however, either in control HbSS cells or those
loaded with Ca2+ (1 μM) using the ionophore bromo-A23187
(6 μM). For example, in Ca2+-loaded cells, the percentage of
cells positive for externalised PS was 47.2 ± 6.0 % in the
absence of WNK463 and 43.2 ± 7.2 % in its presence (both
means ± S.E.M., n = 4, N.S.). Similar findings were found in
red cells from normal individuals. A similar lack of effect was
found in red cells from normal individuals, in which, in the
absence of ionophore, PS exposure was 0.8 ± 0.1% in controls
and 0.8 ± 0.1% following treatment with WNK463.
Discussion
Red cell KCC is sensitive to a number of stimuli including
volume, pH, urea, and oxygen tension [25]. These modalities
appear to affect the transporter by protein (de)phosphorylation
[33, 34], with pharmacological evidence for the presence of
both serine/threonine and tyrosine phosphoresidues [2, 10].
Knockout studies in mice have indicated a role for the Src
and Syk tyrosine kinases [13, 41, 42], with the conjugate
phosphatases identified as PP1, PP2A, or PP2B [2, 3]. More
recent publications provide molecular evidence for a role for
WNK1 and possibly the functionally redundant WNK sub-
strates SPAK/OSR1 in inhibition of KCC and stimulation of
coordinate cotransport, NKCC, in red cells [15, 50, 63]. This
paper provides the first demonstration of a functional role for
WNKs in control of KCl cotransport in red cells from patients
with sickle cell anaemia (SCA).
The main red cell KCC isoform(s) remain(s) uncertain.
Early studies suggested the presence of KCC1, KCC3, and
KCC4 [39]. Later, KCC1 and KCC3 were found to be pre-
dominant, with KCC3 probably being the main KCC in nor-
mal human red cells [45, 51], although the main red cell iso-
forms in other species may vary. In addition, in sickle cells,
normal expression of KCC isoforms may be disrupted [11].
Thus whilst all three isoforms were identified in red cells from
SCA patients, several splice variants were present, and one (of
KCC1) differed quantitatively compared to red cells from nor-
mal individuals [11]. It is not clear to what extent the presence
of different forms of KCC affects the function.
Fig. 6 Effect WNK463 on oxygen-dependent KCC activity in red cells
from patients with SCA. Red cells (20% Hct) were pre-incubated in N-
MBS in the presence or absence of WNK463 (40 nM) at 37 °C in air.
They were then equilibrated in Eschweiler tonometers for 20 min at 0–
150 mmHg, after which aliquots were diluted tenfold into flux tubes, all
in the continued presence or absence of WNK463, and KCC activity was
measured as described in the legend to Fig. 1. Symbols represent means ±
SEM (error bars are smaller than symbols), n = 6
Pflugers Arch - Eur J Physiol (2019) 471:1539–1549 1545
The present work makes use of the pan WNK inhibitor,
WNK463. This inhibitor produced a marked activation of
KCC with an EC50 of around 10 nM, which is about the
concentration reported in the literature for a specific effect
on WNKs. The EC50 of WNK463 for different WNKs varies
and is reported to be 5, 1, 6, and 9 nM forWNKs 1, 2, 3, and 4,
respectively [60]. Our functional assays of KCC activity, how-
ever, are insufficiently sensitive to use these small concentra-
tion differences to identify the main red cell WNK. The EC50
ofWNK463 is very similar to that reported in the literature for
WNKs which is consistent with an action on these enzymes.
An important caveat, however, is that definitive proof of the
role of WNKs awaits phosphorylation studies in mature red
cells or knockdown assays in nucleated red cell precursors.
Nevertheless, as the abnormally high activity of KCC in red
cells from sickle cell patients is known to mediate solute loss
and decrease in cell volume, KCC stimulation induced by
WNK463 would be expected to result in shrinkage.
Both hypertonicity and a reduction of internal [Cl-] have
been shown to activate WNKs [49, 58, 61] leading to an
inhibition of KCC activity. In addition, hypotonicity, some-
times in combination with high [K+], had the opposite effect,
decreasing WNK phosphorylation and activating KCC [15,
62]. Here, hypotonicity, low pH, and urea were used to in-
crease KCC activity which was increased further by treatment
withWNK463. Notwithstanding, the sensitivity to these phys-
iological stimuli was significantly reduced in the presence
WNK463, consistent with the involvement of WNKs, and
widening the stimuli with which these enzymes are associated.
Oxygen is another physiological regulator of KCC and
NKCC in red cells. Until recently the mechanism was un-
known although haemoglobin (Hb) represented the most ob-
vious sensor [27]. Deoxyhaemoglobin has profound effects on
red cell function, acting largely through its greater affinity for
the cytoplasmic tail of band 3 (AE1) compared to
oxyhaemoglobin and from which it displaces several proteins,
including several glycolytic enzymes and ankyrin [7, 40]. In a
similar way, deoxyHb was also recently found to compete
with WNK1 following which its release into the cytoplasm
led to OSR1 activation and subsequent NKCC1 phosphoryla-
tion and activation [63]. As NKCC and KCC are often regu-
lated reciprocally, activation of WNK1 by deoxygenation
would explain phosphorylation and inactivation of KCC. In
SCA, however, KCC activity is abnormally high, and its ab-
errant response to deoxygenation – an increase in activity as
oxygen tension falls from the PO2 of Hb to 0 mmHg –may be
explained if polymerisation of HbS removes the source of
deoxyHb for WNK displacement leading to decreased WNK
activity. The present findings show that inhibiting WNK with
WNK643 not only significantly increased KCC activity but
also abrogated its oxygen dependence.
In previous work in HEK293 cell lines, a major role for
WNK1 was implicated in control of KCC3 activity using
RNA interference (RNAi), with less evidence for WNK2
and WNK4 [50]. In these cells, WNK1 inhibition activated
volume-sensitive KCC3 activity via dephosphorylation of
T991 and T1048. The same residues were dephosphorylated
in hypotonically induced KCC3 activity in red cells, although
no evidence was presented for which WNK was involved.
Phosphorylation of KCC3 T1048 – and its equivalent in the
other KCC isoforms – was later shown to be mediated by
SPAK/OSR1whilst that of T991was not [15, 62], with neither
residue being directly phosphorylated by WNK1 or WNK3.
In the present study, several SPAK/OSR1 inhibitors with dif-
ferent mechanisms of action were tested (STOCK2S-26016,
HK01, closantel, and rafoxanide), but their impact on red cell
KCC activity was minimal.
This apparent paradox could be explained by several ob-
servations. When either T991 or T1048 were mutated to ala-
nine, KCC activity increased moderately and could still be
modulated by low internal [Cl-] or volume change. By con-
trast, T991A/T1048A double mutants were highly active, and
Fig. 7 Effect of SPAK/OSR1 inhibitors onKCC activity in HbAARBCs.
Red cells (40% Hct) were pre-incubated in N-MBS in the presence of 0–
100 μM STOCK2S-26016 or 0–2 mM HK01 at 37 °C in air. They were
then equilibrated in Eschweiler tonometers for 20 min at 0–150 mmHg,
after which KCC activity was measured as described in the legend to Fig.
1. a Effect of STOCK2S-26016 on KCC activity in HbAA cells, n = 3. b
Effect of HK01 on KCC activity in HbAA cells, n = 3. Histograms
represent means ± SEM of n individual samples. * p < 0.05
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the incubation medium had no further impact. Furthermore,
in vitro phosphorylation experiments using purified KCC and
SPAK or OSR1 showed phosphorylation of T1048 but not
T991 [15, 50], whilst in an ES knockin model lacking SPAK
and OSR1 activity, only T991 was phosphorylated [15]. The
effect of a siRNA knockdown of WNK1 in HEK293 was less
clear. It markedly reduced KCC phosphorylation, whilst
knockdown of SPAK or OSR1 did not [50]. It is unclear,
however, if the knockdowns of SPAK and OSR1 were simul-
taneous or separate. If the latter was the case, then one enzyme
could have compensated for the loss of the other. Should
SPAK/OSR1 only be involved in the phosphorylation of
T1048 but that of both T991 and T1048 are required for a full
impact on KCC regulation, inhibiting SPAK/OSR1 would be
expected to have a much smaller effect than inhibiting up-
streamWNK. Further understanding of the pathways control-
ling KCC in red cells awaits identification of the
phosphoresidues involved.
Other pharmacological inhibitors of protein phosphoryla-
tion also increased KCC activity. Staurosporine, which inter-
acts with over two hundred and fifty human kinases with
varying potency, showed a similar effect to WNK463, whilst
a combination of both did not appear to be additive.Moreover,
it has been shown to inhibitWNK1 directly in vitro in an ATP-
dependent manner [59], providing a possible mechanism for
its observed action on KCC activity and lack of any additive
effects. NEM acts via modification of sulfhydryl group of
cysteine residues and has been shown to decrease phosphor-
ylation at an established WNK phosphorylation site in SPAK
required for its activity, as well as at the T1048 equivalent in
KCC2 leading to increased activity in KCC2 transfected
HEK293 cells [8]. Whilst KCC2 is not present in red cells,
these findings suggest a possible mechanism for KCC activa-
tion by NEM. Finally, the effect ofWNK inhibition was large-
ly abrogated by pre-treatment with calyculin A, indicating a
role for protein phosphatases PP1 and PP2A in dephosphory-
lation of the WNK target.
In conclusion, the present findings confirm the involve-
ment of WNK in negative regulation of KCC activity in hu-
man red cells. Whilst this is not a surprise and has been shown
for several tissues, notably epithelia and neurons, there is little
information on its role in red cells aside from a single report on
hypotonically induced KCC activity and, to date, nothing on
sickle cells. In addition, results further emphasise the role of
WNKs in influencing KCC activity by important physiologi-
cal modulators – volume, pH, urea, and oxygen tension.
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